Key result
Programming repeated antitachycardia pacing therapies in the ventricular fibrillation zone remains controversial due to the potential risk of delayed defibrillation.
Why the study?
Does repeated antitachycardia pacing in the ventricular fibrillation zone provide a benefit or pose a risk in patients with implantable cardioverter-defibrillators?
Does repeated antitachycardia pacing in the ventricular fibrillation zone provide a benefit or pose a risk in patients with implantable cardioverter-defibrillators?
Answers are grounded in this paper and cite their sources.
The safety and efficacy of programming repeated antitachycardia pacing in the ventricular fibrillation zone remains controversial due to the potential risk of delayed defibrillation.
Minimizing shocks is an important aspect of care for patients with implantable cardioverter-defibrillators (ICDs). Antitachycardia pacing (ATP) offers an effective, shock-free method for terminating ventricular tachycardias (VTs).1 Several studies have revealed that ATP is more effective in terminating slower VTs with a prolonged VT cycle length (VTCL) than fast VTs with a short VTCL.1,2 Due to the potential risk of delayed defibrillation, programming repeated ATP therapies in the ventricular fibrillation (VF) zone remains controversial.
No takes yet. Share an insight, caveat, or question.
Ikada et al. (2024) conducted an editorial in Patients with implantable cardioverter-defibrillators (ICDs). Repeated antitachycardia pacing (ATP) in the ventricular fibrillation (VF) zone was evaluated. Programming repeated antitachycardia pacing therapies in the ventricular fibrillation zone remains controversial due to the potential risk of delayed defibrillation.
Synapse has enriched 10 related papers. Consider them for comparative context: